Loading...
Gastrointestinal (GI) bleeding is common in patients who receive antithrombotic agents for vascular concerns. When GI bleeding occurs, antithrombotics are usually withheld prior to diagnostic or therapeutic endoscopy. However, when to restart antithrombotic therapy in this setting is often unclear.
To address this issue, investigators conducted a retrospective, long-term, cohort study involving 871 patients (mean age, 78.9 years) who had GI bleeding while receiving therapy with antiplatelet agents, anticoagulants, or both. Of these patients, 811 interrupted therapy after GI bleeding and 60 did not interrupt therapy. Of patients who interrupted therapy, 653 restarted therapy and 158 did not restart therapy. Of those who restarted therapy, two…